Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Richard Charles Curry"'
Autor:
Robert Wesolowski, Anne M. Noonan, Richard Charles Curry, John Charles Morris, Carolyn Muller, Vinay K. Puduvalli, Olivier Rixe, John L. Villano, Trisha Michel Wise-Draper, Emrullah Yilmaz, Gilles Tapolsky, Ray Takigiku
Publikováno v:
Journal of Clinical Oncology. 41:93-93
93 Background: Chemotherapy Induced Peripheral Neuropathy (CIPN) is a debilitating side effect associated with many chemotherapeutic agents. It significantly impacts quality of life during treatment, causes lasting neuropathy, and may also shorten th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b600926c79eca1d6fda41b258b751e73
https://doi.org/10.1200/jco.2023.41.4_suppl.93
https://doi.org/10.1200/jco.2023.41.4_suppl.93
Autor:
Olivier Rixe, Richard Charles Curry, John Charles Morris, Carolyn Muller, Anne M. Noonan, Vinay K. Puduvalli, John L. Villano, Trisha Michel Wise-Draper, Robert Wesolowski, Emrullah Yilmaz, Gilles Tapolsky, Ray Takigiku
Publikováno v:
Journal of Clinical Oncology. 41:154-154
154 Background: Sphingolipids are a class of bioactive signaling molecules implicated in multiple cellular processes and molecular pathways. Many publications have demonstrated that ceramides are proapoptotic, synergize with cancer treatments, and mi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86ec219e4d804e7900198a33328e0221
https://doi.org/10.1200/jco.2023.41.4_suppl.154
https://doi.org/10.1200/jco.2023.41.4_suppl.154
Autor:
Ray Takigiku, Robert Wesolowski, Olivier Rixe, John Charles Morris, Emrullah Yilmaz, John L. Villano, Carolyn Muller, Richard Charles Curry, Vinay K. Puduvalli, Trisha Michel Wise-Draper, Darren Wolfe, Gilles Tapolsky
Publikováno v:
Journal of Clinical Oncology. 40:e15045-e15045
e15045 Background: Chemical Induced Peripheral Neuropathy (CIPN) is a debilitating and serious side-effect associated with many chemotherapeutic treatments. Often, CIPN is a dose-limiting toxicity, and its effects can be long-lasting in some patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78164a56b513a0cf7268aec4fbae82a6
https://doi.org/10.1200/jco.2022.40.16_suppl.e15045
https://doi.org/10.1200/jco.2022.40.16_suppl.e15045
Autor:
Gilles Tapolsky, Olivier Rixe, John Charles Morris, Robert Wesolowski, Emrullah Yilmaz, Anne M. Noonan, John L. Villano, Richard Charles Curry, Carolyn Muller, Trisha Michel Wise-Draper, Vinay K. Puduvalli, Ray Takigiku
Publikováno v:
Journal of Clinical Oncology. 40:e15007-e15007
e15007 Background: BXQ-350 was investigated in a Phase 1 dose-escalation safety study of all-comer cancer patients with advanced solid malignancies, including high grade gliomas ( NCT02859857 ) (safety/efficacy results reported in a separate abstract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91f78013f499e560771ecb57636a7b08
https://doi.org/10.1200/jco.2022.40.16_suppl.e15007
https://doi.org/10.1200/jco.2022.40.16_suppl.e15007
Autor:
Richard Charles Curry, Olivier Rixe, John Charles Morris, Robert Wesolowski, Emrullah Yilmaz, John L. Villano, Carolyn Muller, Trisha Michel Wise-Draper, Anne M. Noonan, Vinay K. Puduvalli, Gilles Tapolsky, Ray Takigiku
Publikováno v:
Journal of Clinical Oncology. 40:e15059-e15059
e15059 Background: Bexion recently completed an all-comer Phase 1 clinical study of BXQ-350 in patients with advanced solid tumors including high grade gliomas to evaluate the safety profile and to determine the maximum tolerated- or biologically eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ca2a51cc49a485b693243d28b85048d
https://doi.org/10.1200/jco.2022.40.16_suppl.e15059
https://doi.org/10.1200/jco.2022.40.16_suppl.e15059
Autor:
Rebecca Fisher, Johanna A. Joyce, Antonio Omuro, Leila Akkari, Marc K. Rosenblum, Richard Charles Curry, Geraldine Faivre, Oscar Lin, Eli L. Diamond
Publikováno v:
Leukemia & Lymphoma. 57:1961-1964
Histiocytic sarcoma (HS) is a rare malignancy that develops from myeloid stem cells. There has been considerable debate over the years as to the correct terminology. In the early twentieth century,...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f93d38501313cc8359123ce7c459427d
https://doi.org/10.3109/10428194.2015.1120867
https://doi.org/10.3109/10428194.2015.1120867
Autor:
Lisa M. DeAngelis, Sean Grimm, K. S. Panageas, Patrick G. Morris, Barbara Grant, Jeffrey J. Raizer, Antonio Omuro, Anne S. Reiner, Sasan Karimi, Lauren E. Abrey, Gaurav D. Shah, Joachim Yahalom, David Schiff, Richard Charles Curry, Rose Lai, Denise D. Correa
Publikováno v:
Journal of Clinical Oncology. 31:3971-3979
Purpose A multicenter phase II study was conducted to assess the efficacy of rituximab, methotrexate, procarbazine, and vincristine (R-MPV) followed by consolidation reduced-dose whole-brain radiotherapy (rdWBRT) and cytarabine in primary CNS lymphom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b6dda58de7ee556c0eefedb127f7c27
https://doi.org/10.1200/jco.2013.50.4910
https://doi.org/10.1200/jco.2013.50.4910
Autor:
Richard Charles Curry, Jeffrey Raizer, Rose Lai, Anne S. Reiner, Katherine S. Panageas, David Schiff, Lauren E. Abrey, Lisa M. DeAngelis, Patrick G. Morris, Joachim Yahalom, Denise D. Correa, Sean Grimm, Barbara Grant, Antonio Omuro
Publikováno v:
Journal of Clinical Oncology. 30:2006-2006
2006 Background: After promising early results in the pilot phase (N= 30) reported by Shah 2007, we report on final results of a multicenter phase II study (N=52) in newly diagnosed PCNSL combining R-MPV-A and rdWBRT, expanded to address long-term di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f12be9dd07c42c5154d612f54e8e85d7
https://doi.org/10.1200/jco.2012.30.15_suppl.2006
https://doi.org/10.1200/jco.2012.30.15_suppl.2006